Go Pro
NASDAQ:GHRS

GH Research Q3 2025 Earnings Report

GH Research logo
$25.96 -1.90 (-6.82%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$25.58 -0.38 (-1.48%)
As of 06:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GH Research EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.23
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

GH Research Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GH Research Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

GH Research's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

GH Research Earnings Headlines

Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the dot-com era split Pets.com from Amazon. One robotics business tied to his research posted $100 million in quarterly revenue, a fifth straight quarter of sequential growth, and 33.4% year-over-year growth. Meanwhile, three hyped names on his avoid list still depend on story over substance. See the full breakdown in his Great AI Shock briefing.tc pixel
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland. Founded in 2018, the company focuses on developing novel therapies for psychiatric and neurological disorders, with an emphasis on treatments that may offer rapid effects.

Its lead program, GH001, is an inhaled formulation of mebufotenin, also known as 5-MeO-DMT, being studied for treatment-resistant depression. GH Research is also developing additional formulations and delivery approaches based on mebufotenin, including the GH002 program. The company’s pipeline remains in clinical development, and it does not currently have marketed products.

GH Research conducts its research and clinical development activities internationally, including in the United States and Europe. The company’s programs are intended for patients with significant unmet needs in psychiatric medicine, subject to the results of clinical trials and regulatory review.

View GH Research Profile